Shield Therapeutics publishes Feraccru Phase III trial in Inflammatory Bowel Disease Journal

Shield Therapeutics (Shield), an independent pharmaceutical company focused on the development of specialist hospital pharmaceuticals announced the online publication of the manuscript of the AEGIS Feraccru (ST10, ferric maltol) Phase III pivotal study in the latest edition of the Inflammatory Bowel Disease Journal, the official journal of the Crohn’s and Colitis Foundation of America.

Source: Pharmacy Europe - January 9, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Haematology feraccru ferric maltol haemoglobin inflammatory bowel disease Latest News publication Source Type: news